Literature DB >> 24847128

Decongestive therapy and renal function in acute heart failure: time for a new approach?

Steven R Goldsmith1, Bradley A Bart2, John Burnett2.   

Abstract

Entities:  

Keywords:  heart failure

Mesh：

Substances：

Year:  2014        PMID： 24847128     DOI： 10.1161/CIRCHEARTFAILURE.113.000828

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN： 1941-3289            Impact factor:   8.790


× No keyword cloud information.
  16 in total

1.  Strategy for monitoring decompensated heart failure treated by an oral vasopressin antagonist with special reference to the role of serum chloride: A case report.

Authors:  Hajime Kataoka; Yu Yamasaki
Journal:  J Cardiol Cases       Date:  2016-09-09

2.  Clinical safety and efficacy of tolvaptan for acute phase therapy in patients with low-flow and normal-flow severe aortic stenosis.

Authors:  Miho Mitsui; Akihisa Kataoka; Yugo Nara; Fukuko Nagura; Hideyuki Kawashima; Hirofumi Hioki; Makoto Nakashima; Yusuke Watanabe; Naoyuki Yokoyama; Ken Kozuma
Journal:  Heart Vessels       Date:  2019-04-16       Impact factor: 2.037

3.  Body fluid regulation via chronic inhibition of sodium-glucose cotransporter-2 in patients with heart failure: a post hoc analysis of the CANDLE trial.

Authors:  Shinya Fujiki; Atsushi Tanaka; Takumi Imai; Michio Shimabukuro; Hiroki Uehara; Ikuko Nakamura; Kazuo Matsunaga; Makoto Suzuki; Takeshi Kashimura; Tohru Minamino; Takayuki Inomata; Koichi Node
Journal:  Clin Res Cardiol       Date:  2022-06-22       Impact factor: 5.460

4.  Favorable effects of early tolvaptan administration in very elderly patients after repeat hospitalizations for acute decompensated heart failure.

Authors:  Masaki Kinoshita; Hideki Okayama; Tetsuya Kosaki; Saki Hosokawa; Go Kawamura; Tatsuya Shigematsu; Tatsunori Takahashi; Yoshitaka Kawada; Go Hiasa; Tadakatsu Yamada; Hiroshi Matsuoka; Yukio Kazatani
Journal:  Heart Vessels       Date:  2017-09-09       Impact factor: 2.037

5.  Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure.

Authors:  Kentaro Jujo; Katsumi Saito; Issei Ishida; Yuho Furuki; Ahsung Kim; Yuki Suzuki; Haruki Sekiguchi; Junichi Yamaguchi; Hiroshi Ogawa; Nobuhisa Hagiwara
Journal:  ESC Heart Fail       Date:  2016-03-31

6.  Dual Impact of Tolvaptan on Intracellular and Extracellular Water in Chronic Kidney Disease Patients with Fluid Retention.

Authors:  Takahiro Masuda; Takuya Murakami; Yusuke Igarashi; Kyochika Okabe; Takahisa Kobayashi; Shin-Ichi Takeda; Takako Saito; Chuji Sekiguchi; Yasuharu Miyazawa; Tetsu Akimoto; Osamu Saito; Shigeaki Muto; Daisuke Nagata
Journal:  Intern Med       Date:  2016-10-01       Impact factor: 1.271

7.  Elevation of arginine vasopressin levels following loop diuretic therapy as a prognostic indicator in heart failure.

Authors:  Shuichi Kitada; Shohei Kikuchi; Hiroo Sonoda; Atsuhiro Yoshida; Nobuyuki Ohte
Journal:  J Int Med Res       Date:  2016-10-27       Impact factor: 1.671

8.  Effects of tolvaptan on urine output in hospitalized heart failure patients with hypoalbuminemia or proteinuria.

Authors:  Koji Takagi; Naoki Sato; Shiro Ishihara; Michiko Sone; Hideo Tokuyama; Kenji Nakama; Toshiya Omote; Arifumi Kikuchi; Masahiro Ishikawa; Kenichi Amitani; Naoto Takahashi; Yuji Maruyama; Hajime Imura; Wataru Shimizu
Journal:  Heart Vessels       Date:  2017-10-23       Impact factor: 2.037

Review 9.  Evidence based review of management of cardiorenal syndrome type 1.

Authors:  Leong Tung Ong
Journal:  World J Methodol       Date:  2021-07-20

10.  Proposal for heart failure progression based on the 'chloride theory': worsening heart failure with increased vs. non-increased serum chloride concentration.

Authors:  Hajime Kataoka
Journal:  ESC Heart Fail       Date:  2017-07-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.